FDA guidance explains presentation of risk information in US drug and device ads
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has explained in a draft guidance the factors it intends to consider when evaluating the advertisements and promotional labelling of prescription drugs and medical devices to ascertain whether they effectively communicate the product’s benefit and risk information1,2.
You may also be interested in...
Pharma Guidelines, ending 1 July 2011
Recently updated and newly issued documents
EuropaBio appoints new chairman
EuropaBio, the European biotech industry association, has appointed Stephan Tanda as its new association chair. Mr Tanda, a member of the managing board of life sciences and materials sciences firm DSM, succeeds GlaxoSmithKline's Andrea Rappagliosi, who will remain a member of the EuropaBio board.
Medtech Guidelines, ending 24 June 2011
Recently updated and newly issued documents